China's drug regulator encourages foreign firms to bring original drugs, high-end medical equipment to domestic production
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 20, Yang Sheng, Deputy Director of China's National Medical Products Administration (NMPA), announced at a State Council Information Office press conference that the agency will support the scaled-up, intensive, and high-end development of the pharmaceutical industry. The NMPA will encourage pharmaceutical enterprises to build smart and green factories. It will continue to support industry development in key regions including the Beijing-Tianjin-Hebei area, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing Twin-City Economic Circle, aiming to cultivate three to five internationally competitive biopharmaceutical innovation clusters. The NMPA will also support expanded openness and cooperation in the pharmaceutical sector by encouraging foreign investment to bring originator drugs and high-end medical equipment into domestic production. Additionally, the agency will support Chinese enterprises in expanding overseas to make Chinese medicines and medical devices available globally.
Source report
September 20 — Yang Sheng, Deputy Director of the National Medical Products Administration (NMPA), announced at a press conference hosted by the State Council Information Office that the agency will promote the scaled-up, intensive, and high-end development of the pharmaceutical industry.
Key initiatives include:
- Encouraging pharmaceutical enterprises to build smart factories and green factories.
- Supporting regional pharmaceutical development in the Beijing-Tianjin-Hebei area, the Yangtze River Delta, the Guangdong-Hong Kong-Macao Greater Bay Area, and the Chengdu-Chongqing Twin-City Economic Circle.
- Cultivating three to five biopharmaceutical innovation clusters with international competitiveness.
- Expanding openness and cooperation in the pharmaceutical sector, including encouraging foreign investment to bring originator drugs and high-end medical equipment into domestic production.
- Supporting Chinese enterprises in expanding overseas, so that Chinese medicines and medical devices can benefit people around the world.
Source
财联社Eastern
Part of this Story
China’s NMPA vows to cultivate 3-5 globally competitive biopharma clusters, boost foreign investment